GLP-1 TV · Patient story · views checked Oct 2026
Geoff Cook (Noom CEO) - The future of compounded GLP-1s
Our summary
Geoff Cook, CEO of Noom, is interviewed on the Hims House podcast about Noom's shift from a behavior change app toward medicated plans. He says that in August more than 50% of Noom's revenue came from its medication plans, up from nearly all revenue being the behavior change program two years ago. He describes Noom's new micro dose GLP-1 program, starting at $119 a month, which uses compounded semaglutide and also includes generic liraglutide. According to Cook, the dose is capped at about 25% of the high maintenance dose, with the aim that 70 plus percent of people have no side effects. He also says he has micro dosed a GLP-1 himself since October 2024, and reports his A1C fell from 5.6 to about 5.2 and he lost 12 pounds.
One person's experience, in their words. Not medical advice.
Where semaglutide costs least today
The three cheapest partner programs for semaglutide, all in per month, checked weekly.
What else the video covers
The hosts then ask about regulation. Cook says he does not expect a deal that ends compounding in exchange for most favored nation drug pricing, citing the 2013 Drug Quality and Security Act and his view that pharma will not cut cash prices enough. He proposes a "high price drug list" tied to the FDA shortage list as a market-based way to bring down prices. He estimates a 200 to 300% tariff on foreign active ingredients could add roughly $30 per vial, or about 10 to 20% of the price.
Cook also discusses the ended partnership with Eli Lilly, which he says is limited by non-disclosure agreements, and says patients can still get Zepbound and Wegovy through Noom's branded program. He closes with views on competition and customer acquisition costs, a planned free tier, and what he expects from GLP-1s, AI and personalized health platforms over the next 10 years.
Our summary of what is said, in our words. Doses, results and prices are the speaker’s, not advice.
Takeaways
The main points, in the order they come up. Tap a time to play from there.
- 2:30 Cook says August was the first month more than 50% of Noom's revenue came from medicated plans rather than its behavior change app.
- 5:42 He says Noom's micro dose program caps the dose at about 25% of the high maintenance dose, aiming for 70 plus percent of people to have no side effects.
- 11:51 Cook says his A1C moved from 5.6 to about 5.2 and he lost 12 pounds on a micro dose of a GLP-1.
- 16:25 He says he does not expect a backroom deal tying compounding limits to most favored nation pricing, and describes his proposed high price drug list.
- 28:08 Cook estimates a 200 to 300% tariff on foreign active ingredients would add roughly $30 per vial, or 10 to 20% of the price.
- 44:00 He says Noom is building a free tier to grow the category beyond paid marketing, and expects GLP-1s to be used in add-on stacks over the next several years.
Key moments
From the creator's own chapters. Tap one to play from there.
- 0:00 Introduction
- 1:11 Noom’s background and evolution
- 5:17 Noom's revenue breakdown: behavioral vs. medicated programs
- 7:22 Launch of GLP-1 microdosing
- 17:44 Geoff’s personal experience with microdosing
- 21:12 Policy and regulatory landscape for GLP-1s
- 24:19 Compounding, MFN pricing, and drug shortages
- 28:38 Noom's WSJ ad for high-priced drug list
What the video says
As stated in the video, not checked by us. Doses and results are the speaker’s, not advice.
- Doses mentioned
- 5 mg
- Side effects mentioned
- hair loss
- Prices mentioned
- $119 a month
- Who is speaking
- Patient
Questions this video answers
What is Noom's micro dose GLP-1 program?
Cook says it starts at $119 a month and uses compounded semaglutide, with generic liraglutide also offered. He says the dose is capped at about 25% of the high maintenance dose, and the goal is for 70 plus percent of people to have no side effects. It includes a companion behavior change program, a muscle defense program and an AI body scan.
Why does Noom's CEO take a micro dose of a GLP-1?
Cook says he began in October 2024 because his A1C was 5.6, which he describes as borderline pre-diabetes. He reports his A1C dropped to about 5.2, his LDL improved and he lost 12 pounds, and he says he became more motivated to exercise. He notes this is anecdotal and based on one person.
How would tariffs on foreign ingredients affect compounded GLP-1 prices?
Cook says the active ingredient is a small part of the cost, perhaps $10 to $15. He estimates a 200 to 300% tariff would add about $30, which he puts at roughly 10 to 20% of the overall price, depending on that price.
Does Noom still offer Zepbound and Wegovy after the Eli Lilly partnership ended?
Cook says Noom no longer has an active partnership with Lilly, and that details are limited by non-disclosure agreements. He says patients can still receive Zepbound and Wegovy through Noom's branded telemedicine program, with prescriptions filled through a pharmacy.
Videos on the same question
The closest videos in the library by what is said in them, not by title.
HEALTH BREAKTHROUGH: Noom unveils proactive GLP-1 programAccording to the video, Noom is launching a proactive health program that combines a micro dose of a GLP-1 medication, regular at-home biomarker blood testing, and Noom's behavior change program.
325. Microdosing GLP-1s Explained with Geoff Cook, CEO of NoomIn this Fitt Insider podcast interview, host Joe Vaneri talks with Geoff Cook, CEO of Noom, about how the company has moved from a behavior change app into clinical care.
Noom CEO on the launch of Noom GLP-1ᴿˣIn this short interview recorded on the New York Stock Exchange floor, the CEO of Noom says he took the job a little over a year ago because of the brand's reach and its mission to help people live better and longer.
Does GLP-1 Microdosing Work? Noom CEO RespondsIn this interview on the On the Pen podcast, host Dave Napman talks with Jeff Cook, who the host introduces as the CEO of Noom.
LifeMD Crashes -27% on GLP-1 Fears... Why I'm Buying The Dip! (LFMD Stock Analysis)The creator of the Beat The Denominator channel explains why they bought LifeMD (LFMD) after the stock fell 27% on a Friday.
Read next
Our guides closest to what this video covers, with prices checked weekly.
- Is Noom legit? What Noom's GLP-1 program costs, its reviews, and its record
Yes. Noom is a real company, and its Noom Med arm prescribes GLP-1s through licensed clinicians. As of October 2026 its own site prices the medication-included Noom GLP-1Rx plan, which is compounded semaglutide, at $129 for the first four weeks, then $279 a month billed as $837 every 12 weeks, though the FAQ on the same page says $249. Trustpilot scores Noom 4.5 across 67,088 reviews, mostly about its app, and we found no FDA warning letter naming it.
- Microdosing GLP-1s: what it saves you, and what it doesn't
Microdosing a GLP-1 does not save money at a compounded seller: none of the compounded programs we track charges less for a smaller dose. Microdosing is not a medical term, and no dose below the label's starting dose has been studied for this. The one microdosing product on our board costs more a month than full-dose compounded tirzepatide at the cheapest seller we track. Where dose really moves the price is the brands; the provider table, per-mg costs and live numbers are below.
- Stopping a GLP-1: what the withdrawal trials found, and what a maintenance dose actually is
Two trials have measured what happens when you stop. On semaglutide, people who lost 17.3% over 68 weeks regained two-thirds of it in the year after stopping, ending 5.6% below where they started. On tirzepatide, people who lost 20.9% in 36 weeks regained 14% over the next year on placebo while those who continued lost a further 5.5%. Both labels are explicit that these drugs are for maintaining weight reduction long term, which is a different claim from finishing a course. A maintenance dose is simply the dose you stay on; the labels do not define a lower one to step down to at goal.
Find more like it
Side effectsDose changeFood, protein and eatingCost and insuranceExercise and strengthStopping and maintenanceThe trialsHair loss
Up next
More from this collection
Watched it? See what it costs.
Every GLP-1 program we track, ranked by what actually leaves your account.